← Leaderboards
Brigitte Angenieux
Ophidion, Inc.
$1,417,567
Attributed
$1,417,567
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $407K · FY2011–16$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,417,567 · 3
By mechanism
R44$793,191 · 1
R43$328,348 · 1
R41$296,028 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoRewardsCell LineMediatingNicotinic ReceptorsBrainMalignant Neoplasm Of LungLeadNicotineInnovationDoseAgonistHealth ExpendituresMarketingIntakeDrug DevelopmentEfficacy TestingBinding (Molecular Function)ConsumptionCigarette SmokingAccountingCostAwardCessation Of Life
Grant awards (4)
Development of a5 nicotinic receptor agonists for smoking cessation$407,007
R44 · FY2016 · DA · contact PI
Development of a5 nicotinic receptor agonists for smoking cessation$386,184
R44 · FY2015 · DA · contact PI
siRNA Mediated Modulation of Lynx1 for Cognitive Enhancement$328,348
R43 · FY2012 · MH · contact PI
In vivo and in vitro tools to target CHRNA5 for smoking cessation.$296,028
R41 · FY2011 · DA · contact PI